Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxininduced toxicity We therefore examined the effects of Ibl0 administration before lipopolysaccharide (LPS) challenge in mice. A marked reduction in the amounts of LPS-induced tumor necrosis factor (TNF) release in the circulation was observed after IL-10 pretreatment at doses as low as 10 U. Ibl0 also efficiently prevented the hypothermia generated by the injection of 100 #g LPS. Finally, pretreatment with a single injection of 1,000 U Ibl0 completely prevented the mortality consecutive to the challenge with 500 #g LPS, a dose that was lethal in 50% of the control mice. We conclude that Ibl0 inhibits in vivo TNF secretion and protects against the lethality of endotoxin in a murine model of septic shock.
Summary
Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxininduced toxicity We therefore examined the effects of Ibl0 administration before lipopolysaccharide (LPS) challenge in mice. A marked reduction in the amounts of LPS-induced tumor necrosis factor (TNF) release in the circulation was observed after IL-10 pretreatment at doses as low as 10 U. Ibl0 also efficiently prevented the hypothermia generated by the injection of 100 #g LPS. Finally, pretreatment with a single injection of 1,000 U Ibl0 completely prevented the mortality consecutive to the challenge with 500 #g LPS, a dose that was lethal in 50% of the control mice. We conclude that Ibl0 inhibits in vivo TNF secretion and protects against the lethality of endotoxin in a murine model of septic shock. E ndotoxin (LPS) from gram-negative bacteria is a major causative agent in the pathogenesis of septic shock (1) . A shock-like state can indeed be induced experimentally by a single injection of LPS into animals. These toxic effects of LPS are mostly related to macrophage activation leading to the release of multiple inflammatory mediators. Among these mediators, TNF appears to play a crucial role, as indicated by the prevention of LPS toxicity by the administration of neutralizing anti-TNF antibodies (2) (3) (4) (5) .
Ibl0 is a recently described cytokine that efficiently blocks the in vitro production of TNF as well as of other cytokines by LPS-activated monocytes/maerophages (6) (7) (8) . Ibl0 might therefore be an efficient agent to downregulate LPS toxicity in vivo. To test this hypothesis, we analyzed the effects of IL-10 administration before LPS challenge in mice, focusing on the systemic release of TNF, hypothermia, and lethality.
Materials and Methods
Animals. 10-15-wk-old BALB/c mice were purchased from the KUL Proef Dieren Centrum (Leuven, Belgium).
Reagents. LPS from Esche6chia coli (serotype O55:B5) was purchased from Sigma Chemical Co. (St. Louis, MO). The JES5-2A5 mAb, a neutralizing rat anti-mouse Ibl0 IgG1 mAb, was kindly given by Tim Mosmann (Department of Immunology, University 1 C. G6rard and C. Bruyns contributed equally to this study.
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of Alberta, Edmonton, Canada) (9) . The LO-DNP mAb, a rat IgG1 antibody used as control, was a kind gift from H. Bazin (Experimental Immunology Unit, Universit6 Catholique de Louvain, Brussels, Belgium).
Mouse Recombinant 1I.,10: Cloning and Expression. Specific oligonucleotides for the murine IL-IO cDNA were synthesized according to its sequence (10), Restriction sites were added to their 5' end for subcloning: HinclI/SaclI for the sense primer 5'-CTC-CATCATGCCTGGCTCA-Y (nucleotide 69-87) and SmaI/XhoI for the antisense primer 5'-TACACACTGCAGGTGTTTTAGC-Y (nucleotide 608-629). Total KNA was prepared from the spleen of mice injected with the hamster anti-CD3 mAb 145-2Cll as a nonspecific stimulator of cytokine transcription (11). 1 #g KNA was reverse transcribed using the antisense oligonudeotide (1/xg) as primer and 200 U Moloney-murine leukemia virus (Mo-MuLV) reverse transcriptase (KT) (Promega Corp., Madison, WI) in KT buffer (50 mM KC1, 20 mM "Iris HC1, pH 8.3, 2.5 mM MgC12, 0.1 mg/ml acetylated BSA, dNTPs 2.5 mM each, KNasin 20 U [Promega Corp.]) in a final volume of 20 #1. To this were added 2.5 U Taq DNA polymerase, and 1 #g of each sense/antisense primer, in the same buffer, and in a total volume of 100 #1. A PCK was performed using a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) for 35 cycles: 1 min denaturation at 94~ 2 rain annealing at 55~ and 3 min extension at 72~ A band with the 560-bp predicted size was obtained. The specificity of the amplified cDNA was validated by its restriction pattern. Sequencing was also performed following the dideoxynucleotide chain termination method (12) . Nucleotides 322, 465-468, 522, and 523 were different from those published (10) , but the amino acids remained unchanged. The SaclI-XhoI restriction fragment, containing the murine IL-10 cDNA, was inserted in the Harvey murine sarcoma virus-derived retroviral vector pCO6-HX in place of the coding sequence of p21 ras (see Fig. 1 ) (13) . In this construction, called pTG1H-mlL10, the IL-10 cDNA is the only functional gene. A similar vector, with no inserted II.-10 gene, was used as negative (mock) control. To derive individual colonies of cells expressing high levels of Ibl0, pTG1H-mlL10 was cotransfected with the plasmid pSV2-neo, which contains the neomycin resistance gene used as a selectable marker. Transfection was performed in the CHO-K1 (Chinese hamster ovarian K1) cell line using a modified calcium phosphate method as described, except that no carrier DNA was present (14) . Selection for transfectants was initiated by adding 400/~g/ml G418 (Geneticin; Gibco, Paisley, Scotland). 10 d later, individual resistant colonies were isolated and tested for IL-10 expression using a specific enzyme-linked immunosorbent assay (Pharmingen, San Diego). IL-10 concentrations were determined by reference to a standard curve of recombinant IL-10 expressed in COS cell supernatant (470 U/ml) (Pharmingen). The supernatant collected after 24 h culture of a colony with high II.-10 level (200 U/ml) was concentrated to 5,000 U IL-10/ml on an ultrafiltration membrane (Amicon Corp., Danvers, MA). Control (mock) supernarant from CHO-K1 cells transfected with the control plasmid and with pSV2-neo has been selected, collected, and concentrated similarly. The endotoxin content of the injected preparations was below 1 ng/ml.
Determination of Serum TNF Levels. Blood samples were obtained from individual mice by retroorbital puncture. Serum levels of TNF were estimated by a cytotoxicity assay on actinomycin-D-treated WEHI-164 clone 13 cells as previously described (15) . Results were expressed in pg/ml in reference to the cytotoxic activity of a standardized (National Biological Standards Board, Hertfordshire, UK) preparation of recombinant murine TNF expressed in Escherichia coli (16) . This preparation had a specific biological activity of 2.25 • 10 s IU/mg, with 1 IU representing about 4 pg routine TNF. We found that IL-10 was not interfering with this bioassay (data not shown). Experimental Protocol. Mice were injected intravenously with 100 #g of LPS 30 min after an intraperitoneal administration of either CHO-IL10 or mock supernatants. Serum TNF levels were determined 1.5, 3, and 6 h after LPS challenge, whereas rectal temperature was measured at regular intervals with a digital thermometer. In another series of experiments, we evaluated the effects of IL-10 on the lethality induced by a single dose of 500 #g LPS. Statistics. TNF levels and temperatures were compared using the Mann-Whitney U test. Lethality data were analyzed with the Fisher's exact test. 
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Results and Discussion
To assess the in vivo effects of ID10 administration on LPSinduced TNF release, three different doses of IL-10 (10, 100, or 1,000 U) were given intraperitoneally 30 min before the intravenous injection of 100 #g LPS. Since previous studies showed that TNF levels peaked 1.5 h after LPS chalhnge, blood samples were taken at that time (17) . II:10 pretreatment resulted in a significant reduction in the amounts of 
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Lethality after injection of 500/~g LPS in three groups of BALB/c mice: (O) mice with no pretreatment (n = 15); (~7) mice pretreated intraperitoneally with 1,000 U I1.-10 (n = 15); (V) mice pretreated intraperitoneally with supernatant from mock-transfected CHO-K1 cells (n = 10). Two-tailedp value has been determined with the Fisher's exact test.
TNF released in the circulation after LPS challenge, as shown in Table I representing one out of three experiments which gave similar results. This in vivo effect of II.-10 was already observed with doses as low as 10 U (p <0.01 as compared with LPS after pretreatment with control medium). As 1,000 U had a more pronounced and reproducible activity, this dose was chosen for further studies. The specificity of the effect of the I1-10 preparation was assessed by pretreating mice with a supernatant from mock-transfected CHO-K1 cells. As shown in Table 1 , this control preparation had no effect on TNF release. TNF serum levels returned to baseline values 3 h after LPS challenge in all groups of mice, indicating that ILl0 did not merely delay the release of TNF ( Table 1) .
As a first approach to evaluate in vivo the effect of I1.10 on LPS-induced toxicity, we monitored rectal temperature for 24 h after challenge with 100/~g LPS. Indeed, as previously reported by others, LPS caused a profound hypothermia which is probably related to TNF release (18) . The data presented in Fig. 2 indicate that II.-10 pretreatment efficiently prevented LPS-induced hypothermia (p <0.0001 at 4 h, and p <0.005 at 6 h, as compared either with LPS alone or LPS after pretreatment with mock superuatant), whereas control superuatant from mock-transfected CHO-K1 cells had no significant effect. A substantial variation in the recovery from hypothermia was seen among the animals injected with 100 /~g LPS, either given alone or after pretreatment with mock supernatant. As an additional control of specificity for the effect observed after pretreatment with CHO-IL10 supernatant, we added 1 mg of the neutralizing anti-mouse I1.10 JES5-2A5 mAb or of a control rat IgG1 LO-DNP mAb to the II.-10 preparation. The anti-I1.10 completely abrogated the protective effect of I1.-10 on hypothermia whereas the control rat mAb had no effect (data not shown).
To evaluate the effect of I1.10 pretreatment on LPS-induced lethality, mice were challenged with 500/~g LPS, a dose which is lethal within 72 h in 50% of the animals. All mice pretreated with 1,000 U II,10 survived the LPS injection, whereas pretreatment with supernatant from mock-transfected CHO-K1 cells did not modify the LPS-induced lethality (Fig. 3) .
Taken together, these data indicate that pretreatment with I1-10 prevents the toxicity of LPS in a murine model of endotoxin shock. The beneficial effect of I1-10 could be due at least in part to the reduction of TNF release. Indeed, a similar level of protection against LPS-induced lethality has been obtained by the use of neutralizing anti-TNF antibodies (2) (3) (4) (5) . In vitro data suggest that I1-10 might also prevent the release of other monocyte/macrophage-derived cytokines involved in the pathogenesis of septic shock, especially I1-1 (1, 6, 19, 20) .
I1.-10 can therefore be added to the potential immunointervention strategies for the prevention and/or treatment of septic shock, which already include anti-TNF mAb (2-5), I1.1 receptor antagonist (21) (22) (23) , differentiation factor/leukemia inhibitory factor (24) , and G-CSF (25) . Because of its deactivation effect on macrophages, I1-10 therapy might be of particular interest, possibly in combination with some of these other biological agents.
